Sector Chart Genome & Company

Equities

End-of-day quote Korea S.E. Other stock markets 23:00:00 03/06/2024 BST			5-day change	1st Jan Change
13,210 ^KRW	+11.57%		+35.35%	+5.76%

01-24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
2023	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes